# Tirzepatide vs Dulaglutide: A Real Head-to-Head

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-11-10

Canonical page: https://glpwatchdog.org/research/tirzepatide-vs-dulaglutide-kidney

> 13,299 people randomized to one drug or the other, followed four years. Kidney events occurred in 6.0% on tirzepatide against 7.6% on dulaglutide, and nausea, vomiting and diarrhea were all more common on tirzepatide.

## Key points

- Composite kidney outcome: 6.0% on tirzepatide against 7.6%, hazard ratio 0.77.
- A rare randomized head-to-head, so no cross-trial comparison is needed.
- Both arms were treated, so this says which drug did better, not how much either beats nothing.
- Nausea, vomiting and diarrhea were all more common with tirzepatide.

Almost every GLP-1 result you read compares a drug against placebo, so comparing two of them usually means setting two separate trials side by side, something this site refuses to do. One trial avoids that problem. It randomized **13,299 people** to either tirzepatide or dulaglutide and followed them a median of four years, so the comparison is inside the randomization rather than across studies.[1] Its heart results, and the Mounjaro indication FDA approved from them, are in [Mounjaro heart protection](https://glpwatchdog.org/research/mounjaro-heart-protection-surpass-cvot). The same trial's all-cause death result is read in [tirzepatide and longevity](https://glpwatchdog.org/research/tirzepatide-and-longevity).

## The result

The primary composite kidney outcome occurred in 396 people on tirzepatide (6.0%) and 498 on dulaglutide (7.6%). That is a 23% lower risk, with a hazard ratio of **0.77** (95% CI 0.68 to 0.88, p=0.0002).[1]

The benefit came from two different places depending on how much kidney disease people started with. In those at low-to-moderate risk, it was driven by fewer new cases of persistent macroalbuminuria, meaning protein appearing in the urine. In those at high risk, it was driven by slower loss of filtration: [the annual decline in eGFR](https://glpwatchdog.org/research/does-weight-loss-fake-kidney-numbers) was lower by 0.29 mL/min per 1.73m² overall, and by 0.93 in the high-risk group.[1]

> **These are two different effects.** Preventing protein from appearing in the urine of someone with healthy kidneys is a different achievement from slowing the decline of kidneys that are already damaged. The trial found each one in the group where it was measurable, and that tells you more than a single averaged number would have.

## What a head-to-head does and does not buy you

The value is that it removes the usual objection. When people set tirzepatide’s weight results beside semaglutide’s, they are reading across trials with different populations and different placebo arms, which is not a real comparison (we make that point in [the tirzepatide timeline](https://glpwatchdog.org/research/tirzepatide-results-timeline)). Here, both groups were enrolled together and assigned at random. Outside this trial, dulaglutide is not a weight drug, and [Trulicity and Wegovy](https://glpwatchdog.org/compare/drugs/trulicity-vs-wegovy) do different jobs: about 3 kg lost at 36 weeks on Trulicity 1.5 mg in AWARD-11, against 14.9% of body weight at 68 weeks on Wegovy in STEP-1.

1. **Both arms were treated.** Nobody received placebo, so this tells you which drug did better, not how much either beats no treatment at all. [Dulaglutide, sold as Trulicity,](https://glpwatchdog.org/research/what-is-trulicity) is an established GLP-1 with its own kidney data, so tirzepatide was beating an active, effective comparator. As weight drugs the two are further apart, since only tirzepatide is approved for weight; see [Zepbound vs Trulicity](https://glpwatchdog.org/compare/drugs/zepbound-vs-trulicity).
2. **It is a pre-specified exploratory analysis of a cardiovascular trial**, not a study designed around kidneys. Pre-specified is far better than picking through results afterward, but the authors label it exploratory, and it is not the same as being the primary question.
3. **The population was specific**: people with type 2 diabetes and atherosclerotic cardiovascular disease, roughly a third of whom already had microalbuminuria at baseline.

## The cost side is in the same abstract

Nausea, vomiting and diarrhea were all more common with tirzepatide than with dulaglutide.[1] The trial states that trade-off itself, and it is the reason a better kidney outcome does not automatically make tirzepatide the better drug for a given person.

> The kidney outcome occurred in 6.0% on tirzepatide against 7.6% on dulaglutide. Nausea, vomiting and diarrhea were all more common on tirzepatide.

For anyone weighing this, our [kidneys article](https://glpwatchdog.org/research/glp1-and-your-kidneys) covers the separate and much larger question of what these drugs do for kidney disease against no treatment, including the acute risk that runs the other way when someone becomes dehydrated.

## Frequently asked questions

### Is tirzepatide better than dulaglutide for the kidneys?

In a randomized comparison of 13,299 people with type 2 diabetes and cardiovascular disease followed a median four years, the primary composite kidney outcome occurred in 6.0% on tirzepatide against 7.6% on dulaglutide, a hazard ratio of 0.77. It is a real difference, in a fair comparison, and modest in absolute terms.

### Why does a head-to-head matter so much?

Because almost everything else in this field compares a drug against placebo, so comparing two drugs usually means reading across separate trials with different populations, which is not a real comparison. Here both groups were enrolled together and assigned at random.

### How did tirzepatide help the kidneys?

Differently depending on starting kidney health. In people at low-to-moderate risk it reduced new-onset persistent macroalbuminuria; in those at high risk it slowed the annual decline in filtration rate, by 0.93 mL/min per 1.73m² a year.

### Are there downsides?

Yes, and the trial reports them: nausea, vomiting and diarrhea were all more common with tirzepatide than with dulaglutide. Better kidney outcomes with worse tolerability make this a trade-off, not a clear upgrade.

### Does this mean everyone should switch?

No. The population studied had type 2 diabetes and established cardiovascular disease, both arms received an active drug, and this was a pre-specified exploratory kidney analysis of a trial designed around cardiovascular outcomes. It is information for a conversation with a prescriber, not a general instruction.

## References

1. Zoungas S, D'Alessio D, Pavo I, et al. A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial. The Lancet Diabetes & Endocrinology. 2026. PMID: 42114520. https://pubmed.ncbi.nlm.nih.gov/42114520/

---

Cite as: GLP Watchdog, Nora Bissett, "Tirzepatide vs Dulaglutide: A Real Head-to-Head", published 2026-08-19, updated 2026-11-10. https://glpwatchdog.org/research/tirzepatide-vs-dulaglutide-kidney

Canonical HTML page: https://glpwatchdog.org/research/tirzepatide-vs-dulaglutide-kidney

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
